DTB: Vol 19, No 4. August - October 2011

Biotechnology drugs and cancer. All that glitters is not gold

Some biotechnology drugs have shown to be useful in the treatment of cancer patients. However, the majority present questionable efficacy, considerable adverse effects and are costly. It is convenient to demonstrate greater scientific rigor when approving or withdrawing these drugs. The public health services should consider selective financing of these drugs in terms of treatment benefits.


Entrevista a Rubén Pío (investigador del CIMA) y a Victoria González (abogada de una asociación de consumidores) sobre los fármacos biotecnológicos en oncología


Responsive Image